Monthly Archives - September 2020

Corbus Pharmaceuticals Announces Topline Results from RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced topline results from the 52-week Phase 3 RESOLVE-1 study of lenabasum in patients with diffuse cutaneous systemic sclerosis (SSc). Read more >>

Managing Your Student Loan Payments During COVID-19

The COVID-19 pandemic has affected nearly every aspect of life on a global scale. As we are forced to observe varying degrees of shelter-in-place and phased reopenings, millions of Americans are out of work and searching for their next paycheck. If you find yourself in this situation and you have student loan debt, you might be worried about making payments. On the other hand, you may be fortunate enough to make your payments but aren’t sure where to start. […]

TRACER to support Akston Biosciences’ Phase 1 clinical study of AKS-452, an innovative anti-COVID-19 vaccine

BEVERLY, Mass., USA & GRONINGEN, the Netherlands, Sept. 01, 2020 Today, TRACER Europe B.V., a Clinical Research Organization (CRO) specializing in fast-track solutions for testing innovative biologic medicines, announced that it will support Akston Biosciences Inc., a leader in the development of novel Fc fusion protein therapeutics, in the Phase 1 clinical testing in the Netherlands of Akston’s lead COVID-19 vaccine candidate, AKS-452. Read more >>